Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Bioharvest Sciences (BHST) EBT (2023 - 2025)

Bioharvest Sciences has reported EBT over the past 3 years, most recently at -$2.3 million for Q4 2025.

  • For Q4 2025, EBT rose 23.07% year-over-year to -$2.3 million; the TTM value through Dec 2025 reached -$11.1 million, up 14.3%, while the annual FY2025 figure was -$11.1 million, 14.3% up from the prior year.
  • EBT was -$2.3 million for Q4 2025 at Bioharvest Sciences, up from -$2.4 million in the prior quarter.
  • Across five years, EBT topped out at $7.2 million in Q4 2023 and bottomed at -$6.6 million in Q1 2024.
  • The 3-year median for EBT is -$2.3 million (2025), against an average of -$1.1 million.
  • The widest YoY moves for EBT: up 65.05% in 2025, down 488.21% in 2025.
  • Over 3 years, EBT stood at $7.2 million in 2023, then plummeted by 140.75% to -$2.9 million in 2024, then grew by 23.07% to -$2.3 million in 2025.
  • The last three reported values for EBT were -$2.3 million (Q4 2025), -$2.4 million (Q3 2025), and -$4.0 million (Q2 2025) per Business Quant data.